SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

Exclusion Criteria

• •Pregnant or breast-feeding
• •Current malignancy with the exceptions of localized basal cell or squamous cell skin cancer or localized prostate cancer or is receiving immunotherapy, chemotherapy or radiation therapy for a malignancy
• •Current myelodysplastic syndrome
• •Alanine aminotransferase (ALT) \>4 times the upper limit of normal, decompensated cirrhosis, or ascites at screening
• •Past history of clinically significant kidney disease (per the Principal Investigator)
• •Serum creatinine greater than the upper limit of normal during screening
• •Urine protein to creatinine ratio \> 0.5 mg/mg during screening
• •Ongoing symptoms of cardiac dysfunction or failure
• •Ongoing symptoms of neuropathy, including peripheral sensory neuropathy, peripheral motor neuropathy, or paresthesia at screening
• •Received another investigational drug within 30 days or investigational antibody within 90 days of Day 1 of the study
• •Other condition that, in the opinion of the PI, would interfere with the conduct of the study